ClinicalTrialsFinder
RecruitingPhase 2Phase 3NCT06879145

Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

A Randomized, Open, Multicenter Phase II/III Clinical Study of SHR-A2102 for Injection Combined With Adebrelimab (SHR-1316) in Perioperative Treatment of Muscular Invasive Bladder Cancer (MIBC)

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrollment

840 participants

Start Date

Apr 25, 2025

Study Type

INTERVENTIONAL

Conditions

Muscular Invasive Bladder Cancer (MIBC)

Summary

In phase II, the main objective is to evaluate the efficacy of SHR-A2102 combined with Adebrelimab in the treatment of muscular invasive bladder cancer (MIBC); The main objective of phase III is to evaluate the efficacy of SHR-A2102 for injection combined with Adebrelimab compared with gemcitabine combined with cisplatin in the treatment of muscular invasive bladder cancer (MIBC).

Eligibility

Min Age: 18 Years

Inclusion Criteria7

  • Age over 18 years old, gender not limited.
  • The patient voluntarily joined this study and signed informed consent
  • ECOG score is 0 or 1
  • Expected survival period ≥ 2 years.
  • Pathology and imaging diagnosis of non metastatic muscle invasive bladder cancer
  • There are assessable lesions that meet the RECIST 1.1 criteria
  • Enough organ function

Exclusion Criteria10

  • Received systemic anti-tumor therapy 4 weeks before starting the study treatment
  • The toxicity and/or complications of previous anti-tumor treatments have not recovered to NCI-CTCAE ≤ 1 level
  • Subjects known or suspected to have interstitial pneumonia
  • Individuals with any active, known or suspected autoimmune diseases
  • There are clinical symptoms or diseases of the heart that have not been well controlled
  • Diagnosed with any other malignant tumor
  • Subjects who have experienced severe infections within 28 days prior to their first medication use
  • History of immunodeficiency
  • Use of attenuated live vaccine within 28 days prior to the first study medication
  • Have undergone major surgery within 28 days prior to the first administration of medication

Interventions

DRUGSHR-A2102；Adebrelimab

Treatment with SHR-A2102 in combination with fixed dose Adebrelimab

Locations(1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06879145